A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
This article, published in the New England Journal of Medicine, reports results from a pivotal, large-scale Phase 3 trial of RTS,S/AS01 malaria vaccine. When compared to immunization with a control vaccine, infants (aged 6 to 12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria and had similar reactions to the injection. In this trial, RTS,S demonstrated an acceptable safety and tolerability profile.
Author: The RTS,S Clinical Trials Partnership
» Visit web page (English)
(Located at www.nejm.org)
Citation: The RTS,S Clinical Trials Partnership. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine. 2012;367:2284-2295.
Resource types: Peer-reviewed journal